“…This is particularly true in first-line or early-relapse settings, given the potential exposure to multiple additional lines of therapy, particularly including highly active agents such as daratumumab. 11 Although, as noted by Mohyuddin et al, 1 OS remains important in determining whether combining drugs is better than simply sequencing them, studies are usually not designed to investigate this because subsequent lines are not controlled per protocol. Conversely, OS may remain a practical end point in advanced disease patients, who may not be expected to receive extensive subsequent lines.…”